Nasdaq Auph News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq auph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Auph Today - Breaking & Trending Today
Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 9.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,634 shares of the biotechnology company’s stock after purchasing an additional 2,390 shares during the quarter. […] ....
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 10,650,000 shares, a decrease of 12.0% from the February 29th total of 12,100,000 shares. Based on an average daily trading volume, of […] ....
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) rose 4.6% during mid-day trading on Monday . The stock traded as high as $5.25 and last traded at $5.24. Approximately 959,196 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 2,388,016 shares. The stock had previously closed at […] ....
Aurinia Pharmaceuticals (NASDAQ:AUPH – Free Report) (TSE:AUP) had its price objective decreased by Cantor Fitzgerald from $12.00 to $10.00 in a research note published on Friday morning, Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the company. Jefferies Financial Group […] ....
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) had its price target reduced by stock analysts at HC Wainwright from $15.00 to $13.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential […] ....